Weight gain during treatment with antipsychotics: Clinical relevance, pathophysiology, and therapeutical strategies;Gewichtszunahme während der behandlung mit antipsychotika: Klinische relevanz, pathophysiologie und therapeutische möglichkeiten

Psychiatrische Praxis, Supplement

Volumn 31, Issue 2, 2004, Pages

  Himmerich, Hubertus ^a   Schuld, Andreas ^b   Pollmächer, Thomas ^b  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b KLINIKUM INGOLSTADT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CLOZAPINE; EPHEDRINE; HALOPERIDOL; METFORMIN; MONOAMINE OXIDASE INHIBITOR; NALTREXONE; NEUROLEPTIC AGENT; NIZATIDINE; OLANZAPINE; REBOXETINE; RISPERIDONE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE;

BEHAVIOR THERAPY; DIET THERAPY; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; HUMAN; MENTAL DISEASE; MORBIDITY; NEUROTRANSMISSION; OBESITY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; REVIEW; RISK FACTOR; WEIGHT GAIN;

EID: 10844236367     PISSN: 16118332     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-828475     Document Type: Review

References (56)

1. Himmerich H, Schuld A, Pollmächer T. Gewichtszunahme unter Psychopharmakotherapie und ihre klinische Bedeutung. Dt Ärztebl, 2004, im Druck
2. Pijl H, Meinders AE. Bodyweight change as an adverse effect of drug treatment. Mechanisms and management. Drug Saf 1996; 14: 329-342
3. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-1696
4. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003; 61: 123-136
5. Silverstone T, Smith G, Goodall E. Prevalence of obesity in patients receiving depot antipsychotics. Br J Psychiatry 1988; 153: 214-217
6. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62: 22-31
7. Stedman T, Welham J. The distribution of adipose tissue in female inpatients receiving psychotropic drugs. Br J Psychiatry 1993; 162: 249-250
8. Aronne LJ. Epidemiology, morbidity, and treatment of overweight and obesity. J Clin Psychiatry 2001; 62: 13-22
9. Kraepelin E. Lectures on Clinical Psychiatry. New York: William Wood & Company, 1904
10. Kryspin-Exner W. Beiträge zum Verlauf des Körpergewichtes bei Psychosen. Wiener Klinische Wochenschrift 1947; 59: 531-534
11. Klett CJ, Caffey EM. Weight changes during treatment with phenothiazine derivates. J Neuropsychiatry 1960; 2: 102-108
12. Singh MM, Dios LV De, Kline NS. Weight as a correlate to clinical response to psychotropic drugs. Psychosomatics 1970; 11: 562-570
13. Czobor P, Volavka J, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Cooper TB, Chakos M, Lieberman JA. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol 2002; 22: 244-251
14. Gordon HL, Groth C. Weight change during and after hospital treatment. Arch Gen Psychiatry 1964; 10: 115-119
15. Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker WW. Weight gain induced by clozapine. Eur Neuropsychopharmacol 1995; 5: 437-440
16. Himmerich H, Schuld A, Haack M, Kaufmann C, Pollmächer T. Early prediction of changes in weight during six weeks of treatment with antidepressants. J Psychiatr Res, 2004, im Druck
17. Stunkard AJ, Fernstrom MH, Price A, Frank E, Kupfer DJ. Direction of weight change in recurrent depression. Arch Gen Psychiatry 1990; 47: 857-860
18. Baptista T, Teneud L, Contreras Q, Alastre T, Burguera JL, Burguera M de, Baptista E de, Weiss S, Hernandez L. Lithium and body weight gain. Pharmacopsychiatry 1995; 28: 35-44
19. Paykel ES, Mueller PS, Del V. Amitriptyline, weight gain and carbohydrate craving: a side effect. Br J Psychiatry 1973; 123: 501-507
20. Zimmermann U, Kraus T, Himmerich H, Schuld A, Pollmächer T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 2003; 37: 193-220
21. Planansky K, Heilizer F. Weight changes in relation to the characteristics of patients on chlorpromazine. J Clin Exp Psychopathol 1959; 20: 53-57
22. Shen WW. A history of antipsychotic drug development. Compr Psychiatry 1999; 40: 407-414
23. Schwartz MW, Woods SC, Porte DJ, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 2000; 404: 661-671
24. Kraus T, Haack M, Schuld A, Hinze-Seich D, Kühn M, Uhr M, Pollmächer T. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999; 156: 312-314
25. Hegyi K, Fulop KA, Kovacs KJ, Falus A, Toth S. High leptin level is accompanied with decreased long leptin receptor transcript in histamine deficient transgenic mice. Immunol Lett 2004; 92: 193-197
26. Masaki T, Yoshimatsu H, Chiba S, Watanabe T, Sakata T. Targeted disruption of histamine H1-receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice. Diabetes 2001; 50: 385-391
27. Hauner H, Bender M, Haastert B, Hube F. Plasma concentrations of soluble TNF-alpha receptors in obese subjects. Int J Obes Relat Metab Disord 1998; 22: 1239-1243
28. Borst SE. The role of TNF-alpha in insulin resistance. Endocrine 2004; 23: 177-182
29. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95: 2111-2119
30. Schuld A, Kraus T, Haack M, Hinze-Selch D, Kuhn M, Pollmächer T. Plasma levels of cytokines and soluble cytokine receptors during treatment with olanzapine. Schizophr Res 2000; 43: 164-166
31. Hinze-Selch D, Deuschle M, Weber B, Heuser I, Pollmächer T. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. Psychopharmacology 2000; 149: 163-169
32. Pollmächer T, Hinze-Selch D, Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 1996; 16: 403-409
33. Pollmächer T, Hinze-Selch D, Fenzel T, Kraus T, Schuld A, Mullington J. Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. Am J Psychiatry 1997; 154: 1763-1765
34. Kraus T, Zimmermann U, Schuld A, Haack M, Hinze-Selch D, Pollmächer T. Zur Pathophysiologie der Gewichtsregulation im Rahmen der Therapie mit Psychopharmaka. Fortschr Neurol Psychiatr 2001; 69: 116-137
35. Astrup A, Toubro S, Cannon S, Hein P, Madsen J. Thermogenic synergism between ephedrine and caffeine in healthy volunteers: a double-blind, placebo-controlled study. Metabolism 1991; 40: 323-329
36. McNeely W, Goa KL. Sibutramine. A review of its contribution to the management of obesity. Drugs 1998; 56: 1093-1124
37. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-lowcalorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999; 106: 179-184
38. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235-242
39. Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metabol Dis 2000; 24: 306-313
40. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998; 352: 167-172
41. Anghelescu I, Klawe C, Benkert O. Orlistat in the treatment of psychopharmacologically induced weight gain. J Clin Psychopharmacol 2000; 20: 716-717
42. Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry 2000; 45: 198
43. Stoa-Birketvedt G, Paus PN, Ganss R, Ingebretsen OC, Florholmen J. Cimetidine reduces weight and improves metabolic control in overweight patients with type 2 diabetes. Int J Obes Relat Metabol Dis 1998; 22: 1041-1045
44. Stoa-Birketvedt G. Effect of cimetidine suspension on appetite and weight in overweight subjects. BMJ 1993; 306: 1091-1093
45. Sacchetti E, Guarneri L, Bravi D. H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. Biol Psychiatry 2000; 48: 167-168
46. Yim GK, Lowy MT. Opioids, feeding, and anorexias. Fed Proc 1984; 43: 2893-2897
47. Bertino M, Beauchamp GK, Engelman K. Naltrexone, an opioid blocker, alters taste perception and nutrient intake in humans. Am J Physiol 1991; 261: R59-R63
48. Levine AS, Billington CJ. Opioids. Are they regulators of feeding? Ann N Y Acad Sci 1989; 575: 209-219
49. Zimmermann U, Rechlin T, Plaskacewicz GJ, Barocka A, Wildt L, Kaschka WP. Effect of naltrexone on weight gain and food craving induced by tricyclic antidepressants and lithium: an open study. Biol Psychiatry 1997; 41: 747-749
50. Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 2002; 159: 655-657
51. Floris M, Lejeune J, Deberdt W. Effect of amantadine on weight gain during olanzapine treatment. Eur Neuropsychopharmacol 2001; 11: 181-182
52. Correa N, Opler LA, Kay SR, Birmaher B. Amantadine in the treatment of neuroendocrine side effects of neuroleptics. J Clin Psychopharmacol 1987; 7: 91-95
53. Kamath V, Jones CN, Yip JC, Varasteh BB, Cincotta AH, Reaven GM, Chen YD. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diabetes Care 1997; 20: 1697-1701
54. Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, Pipek R, Iozzo P, Lancaster JL, Cincotta AH, DeFronzo RA. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 2000; 23: 1154-1161
55. Poyurovsky M, Isaacs I, Fuchs C, Schneidman M, Faragian S, Weizman R, Weizman A. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatry 2003; 160: 297-302
56. Baptista T, Zarate J, Joober R, Colasante C, Beaulieu S, Paez X, Hernandez L. Drug induced weight gain, an impediment to successful pharmacotherapy: Focus on antipsychotics. Curr Drug Targets 2004; 5: 279-299